Our Team

Dr. Tepper has over 30 years of experience in the biotechnology and pharmaceutical industry.  He has led drug discovery & drug development programs that span a wide range of therapeutic areas including Oncology, Immunology, Rheumatology, Endocrinology, Metabolic Diseases, CNS, Inflammation and Pain. Following a 15-year career in large Pharma R&D, in 2002 Dr Tepper left large Pharma to become a serial entrepreneur where he founded multiple successful biotech companies.  In leading these companies, he served on the executive management team, helping to execute on the business & commercialization plan. In the last 15 years, Dr. Tepper has raised over $200M in capital for his ventures. He has taken two of his companies’ public (Corbus Pharmaceuticals and RXi Pharmaceuticals) and sold another company (Primatope sold to Kiniksa) in a trade sale.  

Dr. Tepper earned a Ph.D. in Biochemistry & Biophysics from Columbia University, College of Physicians and Surgeons, New York, and a B.A in Chemistry with Highest Honors from Clark University, Worcester, Mass. He did his postdoctoral fellowship at University of Massachusetts Medical School, Worcester in the laboratory of Michael P. Czech. He has over 50 scientific publications and is the co-inventor of multiple drug related patents.

Dr. Marshall brings 25+ years of experience across all aspects of clinical research including translational, Phase 1-3, and post-marketing studies in academia, startup, and mid-sized biopharmaceutical companies. In biotech, Dr. Marshall has developed and led programs across multiple CNS disorders, both neurology and psychiatry, in rare disease, and in hepatology and pediatric oncology. Most recently, Dr. Marshall co-founded ProTara Therapeutics as Chief Medical Officer, a clinical-stage rare disease company recently listed on NASDAQ. Prior to that, he held medical leadership roles of increasing responsibility at Sepracor, Sunovion, Euthymics, Neurovance, and Retrophin.

Dr. Marshall earned his MD at Johns Hopkins University and completed his Psychiatry residence at Columbia University, where he attained Associate Professor before leaving to pursue therapeutics research in biotechnology. At Columbia, he was PI, Co-PI, or Advisor to ~30 research grants funded through NIH, nonprofits and industry, and he has published more than 130 peer-reviewed publications, book chapters or books in his fields of expertise.

Dr. Larrick is a pioneer of the biotechnology industry.  His work on therapeutic antibodies and other protein therapeutics has spanned the entire range of biopharmaceutical product development from target discovery, process science to advanced clinical trials.

He began his career as director of research at Cetus Immune Research Labs, ultimately acquired by Novartis for $5.1 billion. While at Cetus (later Chirion), Dr. Larrick developed technologies that were critical to the practical development of recombinant antibodies.  In 1991, Dr. Larrick founded the Panorama Institute of Molecular Medicine (PRI), where he has led in the discovery and early development of drug candidates addressing major unmet needs in cancer, infectious, autoimmune, cardiovascular, neurological, and metabolic diseases. PRI has incubated more than 20 life science projects which have led to five IPOs and numerous successful acquisitions.

Dr. Larrick holds M.D. and Ph.D. degrees from Duke University School of Medicine, and completed his residency in internal medicine at Stanford Medical Center followed by a postdoctoral fellowship in the Stanford Cancer Biology Research Labs. In addition to leading PRI, he is chairman of the biomedical screening committee of the Life Science Angels, is a co-founder and Board member of Eumentis, and serves on the boards of several biotechnology companies. Dr. Larrick has written or co authored eight books, over 250 papers/chapters, and over 30 patents, and he has served on the editorial boards of six journals.

Catherine has worked in medicinal product development since 1998 in both pharmaceutical companies and CROs, focusing on Regulatory Affairs since 2001, giving her wide-ranging experience of regulatory affairs relating to prescription and over the counter (OTC) products as well as generics and medical devices.  She has managed worldwide clinical trial applications, marketing applications and associated regulatory lifecycle maintenance, pre- and post-marketing.  Before joining TMC Pharma in 2017, Catherine held the position of Director of Global Regulatory Affairs at a large CRO, where she led a team of over 60 people in the UK, Ukraine, Russia and Georgia and also led the company’s regulatory process improvement activities. 

Catherine gained her dual Honours BSc degree in Biochemistry and Biology in 1998 FROM Keele University. She is also a member of The Organization for Professionals in Regulatory Affairs (TOPRA).  Catherine and her team at TMC have extensive experience working with agencies around the globe, as well as the FDA, and successful submissions and interactions including multiple INDs and MAAs.

‍

Joanne has over 25 years of experience in the industry, from academic research in Multi-Organ Transplant Research space at the University of Western Ontario, through a distinguished  career in leadership roles at both  large and mid-sized CROs including PRA and Premier Research. Her experience ranges across clinical operations, project management, study start-up, resourcing, and therapeutics-driven oversight, always with a keen focus on customer accountability for study delivery.

Joanne currently provides sponsor-focused consulting to emerging biotech and small pharma companies on overall clinical operational strategy and execution, including building outsourcing methods, creating and growing operational teams, and best practices vendor engagement and oversight.

Dr. Zhang has over 25 years of experience in developing small molecules, conjugated peptides, small molecule-drug conjugates, and biologics including antibody-drug conjugates. Most recently he was the Chief Technical Officer of Vincerx Pharma, responsible for strategy, planning and execution of all CMC activities. Previously, Dr. Zhang was a Venture Partner at Velocity Pharmaceutical Development, where he played an integral role in the launching and development of several project-focused companies, including Menlo Therapeutics, Corsair and Spitfire. Early in his career, Dr. Zhang held various scientific and program leadership positions at Roche, Millennium Pharmaceuticals and Portola Pharmaceuticals, where he contributed to the discovery and development of several new molecular entities.

Dr. Zhang received his Ph.D. from the University of Maryland, College Park, in the field of synthetic organic chemistry, and pursued postdoctoral research at the University of California, Berkeley. He is an inventor on 55 issued US patents.